Results 21 to 30 of about 743 (109)

Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‐on First Italian netwoRk Study (BRIVAFIRST) [PDF]

open access: yes, 2022
BACKGROUND: The management of epilepsy in older adults has become part of daily practice because of an aging population. Older patients with epilepsy represent a distinct and more vulnerable clinical group as compared with younger patients, and they are ...
Chiesa V.   +443 more
core   +7 more sources

Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures: A multicenter, open‐label, single‐arm study

open access: yesEpilepsia Open, 2023
Objective To evaluate the pharmacokinetics (PK), safety, and tolerability of brivaracetam (BRV) in neonates with repeated electroencephalographic seizures not controlled with previous antiseizure medications (ASMs).
Ronit Pressler   +9 more
doaj   +2 more sources

Emerging drugs for partial-onset epilepsy: a review of brivaracetam

open access: yesTherapeutics and Clinical Risk Management, 2016
Lan Gao,1 Shuchuen Li2 1Deakin Population Health SRC, Faculty of Health, Deakin University, Burwood, Victoria, 2School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia Abstract: There are more than 12 new ...
Gao L, Li SC
doaj   +1 more source

Brivaracetam to Treat Partial Onset Seizures in Adults [PDF]

open access: yes, 2022
PURPOSE OF REVIEW: Seizures are a hyperexcitable, and hypersynchronous imbalance between excitatory and inhibitory factors (E/I imbalance) in neurotransmission, and epilepsy is the recurrent manifestation of seizures within a reasonable time frame and ...
Le, David   +27 more
core   +1 more source

A VALIDATED LC-MS/MS METHOD FOR PHARMACOKINETIC STUDY OF BRIVARACETAM IN HEALTHY RABBITS [PDF]

open access: yes, 2018
Objective: A liquid chromatography-tandem mass spectrophotometric (LC–MS/MS) method was developed for quantification of brivaracetam in rabit plasma employing liquid-liquid extraction with ethyl acetate.Methods: Developed method was validated for ...
D. Atul Vasanth, B. Rajkamal
core   +3 more sources

A Brief Review of Analytical Methods for the Estimation of Brivaracetam in Pharmaceutical Formulation and Biological Matrices [PDF]

open access: yes, 2022
Partial-onset seizures are treated with Brivaracetam, which is a chemical butanamide derivative. Brivaracetam (BRV) in pharmaceutical and biological samples can be determined using various analytical techniques, including HPLC, UV-visible, and hybrid ...
Kiran Kumar Aalapati   +2 more
core   +1 more source

Safety and efficacy of brivaracetam in children epilepsy: a systematic review and meta-analysis

open access: yesFrontiers in Neurology, 2023
BackgroundEpilepsy is one of the most common neurological diseases, affecting people of any age. Although the treatments of epilepsy are more and more diverse, the uncertainty regarding efficacy and adverse events still exists, especially in the control ...
Ting Song   +6 more
doaj   +1 more source

Effect of Brivaracetam on Efficacy and Tolerability in Patients With Brain Tumor-Related Epilepsy: A Retrospective Multicenter Study

open access: yesFrontiers in Neurology, 2020
Background: Epilepsy is a common symptom of brain tumors and is often pharmacoresistent. Among new antiseizure medications (ASMs) Brivaracetam (BRV) has been approved as adjunctive treatment for focal seizures and it was tested in non-oncological patient
Marta Maschio   +8 more
doaj   +1 more source

First-year Experience with Brivaracetam in Japan: Real-world Data from Juntendo Epilepsy Center

open access: yesNeurologia Medico-Chirurgica
Approximately 30% of patients still develop drug-resistant epilepsy despite the introduction of newer antiseizure medications. Brivaracetam, a high-affinity synaptic vesicle protein 2A ligand with a mechanism of action similar to that of levetiracetam ...
Yasushi IIMURA   +9 more
doaj   +1 more source

Brivaracetam and levetiracetam dose adjustments leading to behavioural adverse effects

open access: yes, 2017
With the recent approval of brivaracetam, the high-affinity synaptic vesicle protein 2A (SV2A) ligand, it has previously been suggested that patients on levetiracetam may benefit from switching to brivaracetam.1 The behavioural issues related to its ...
May Yung Tiet, Jithin George
core   +1 more source

Home - About - Disclaimer - Privacy